Gemcitabine SR is under clinical development by Sustained Therapeutics and currently in Phase III for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase III drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Gemcitabine SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemcitabine SR overview
Gemcitabine (ST-02) is under development for the treatment of upper tract urothelial carcinoma. It acts by targeting ribonucleoside diphosphate reductase subunit M1. It is administered in the form of suspension into the upper urinary tract via a catheter.
Sustained Therapeutics overview
Sustained Therapeutics (Sustained) provides bio technology, healthcare, pharmaceutical, life sciences and other services. Sustained is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of Gemcitabine SR’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
